ImmunoGen Undervalued In AbbVie Deal, Shareholder Claims
Law 360
JANUARY 8, 2024
A shareholder alleges that ImmunoGen Inc. directors and advisers significantly undervalued the company while preparing to sell to AbbVie Inc., including by failing to consider the $1.6 billion in projected revenue from a new ovarian cancer drug, according to a suit filed Monday.
Let's personalize your content